Imagine visiting your doctor’s office. Instead of swiping a co-pay card and filling out a…
AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis…
On Tuesday, Curebase announced a three-year clinical trial partnership with Meru Health, the study looking…
Thousands of patients with a particular form of breast cancer in England and Wales can…
Tony Estrella is many things – a podcast host, a novelist, a digital health strategist,…
Chances of FDA approval for Spectrum Pharma’s lung cancer candidate poziotinib and Oncopeptides’ Pepaxto for…
By now, we’re all (hopefully) getting accustomed to the concept of “patient-centricity.” However, another commonly…
Eli Lilly’s tissue-agnostic cancer drug Retevmo has just had its eligible patient population increased in…
There is little doubt that the arrival of COVID-19 changed the game for communication and…
With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out…
GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem…
After a torrid couple of years, Biogen can be forgiven for making the most of…
California biotech Calibr and partner AbbVie have reported the first clinical data on a new…
Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM,…
Insulin has been used to manage diabetes for a century, and while many advances have…
BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be…
The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire…
Although a tone of respectful sobriety lay over the PM Society Awards this year, as…
Novartis is running out of options in its bid to defend oral muscular sclerosis therapy…
Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib…
- Pharma News
The 13th PM Society Digital Awards – celebrating creative innovation & efficacy in healthcare
Although a tone of respectful sobriety lay over the PM Society Awards this year, as…
New book sets the pharmaceutical industry on a course for bridging the patient centricity optimism…
Three years after it started working with Pfizer, artificial intelligence-powered drug discovery specialist CytoReason has…
Aurinia Pharma and partner Otsuka have secured approval in the EU or Lupkynis, billed as…
Novartis’ soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of…
Findings from the litifilimab trial, undertaken by Northwell Health’s Division of Rheumatology and The Feinstein…
It’s well known that where you live can have a profound impact on your risk…
COVID-19 is still circulating and there are fears that further spikes in cases are to…
French pharma company Genfit has reached a deal to buy Versantis of Switzerland, adding three…
Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching,…
Prospects for AstraZeneca’s oral Factor D inhibitor danicopan were looking poor after it failed a…
Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for…
George Medicines has partnered with Medisante to provide technology for a study of an experimental…
Bristol-Myers Squibb’s Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients…
Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug…
Pharmaphorum Editor-in-Chief Jonah Comstock welcomes Matt Dugan, director and head of innovation at Novo Nordisk,…
Pfizer’s close-fought contest with GSK to bring a next-generation meningitis vaccine to market has entered…
The Clinical Data Interchange Standards Consortium (CDISC) is dedicated to the improvement of medical research through data…
The competition authorities in Switzerland said this morning they have carried out a raid on…
Mallinckrodt has finally claimed FDA approval for terlipressin as a treatment for hepatorenal syndrome (HRS),…
Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A…
Aldeyra Therapeutics’ dogged persistence with its drug eye disease therapy reproxalap – despite mixed results…
The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal…
The potential for technology to transform the way we deliver healthcare is nothing new. We’ve…
SparingVision has raised €75 million in second-round funding that will be used to fund clinical…
A $14 million research project is getting underway in the US to see whether cancer…
Bayer chief executive Werner Baumann has been under fire from investors since he spearheaded the…
After years of stagnation in the treatment of neurodegenerative disorder amyotrophic lateral sclerosis (ALS), patients…
- Pharma News
Rethinking trial engagement and recruitment starts with patient perspectives: patient survey insights
With countless media stories regarding COVID-19 published over a period of several years, it was…
A drug developed by US biotech Akero Therapeutics has hit the mark in a phase…